Edge Therapeutics, Inc. – Product Pipeline Review – 2012
SUMMARY
Global Market Direct’s pharmaceuticals report, “Edge Therapeutics, Inc. Product Pipeline Review - 2012” provides data on the Edge Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Edge Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Edge Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
SCOPE
SUMMARY
Global Market Direct’s pharmaceuticals report, “Edge Therapeutics, Inc. Product Pipeline Review - 2012” provides data on the Edge Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Edge Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Edge Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
SCOPE
- Edge Therapeutics, Inc. - Brief Edge Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Edge Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Edge Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Edge Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Edge Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Edge Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Edge Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Edge Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Edge Therapeutics, Inc. and identify potential opportunities in those areas.
Edge Therapeutics, Inc. Snapshot
Edge Therapeutics, Inc. Overview
Key Information
Key Facts
Edge Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Edge Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Edge Therapeutics, Inc. – Pipeline Products Glance
Edge Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Edge Therapeutics, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Edge Therapeutics, Inc. – Drug Profiles
aminocaproic acid
Product Description
Mechanism of Action
R&D Progress
EG-1960
Product Description
Mechanism of Action
R&D Progress
EG-1967
Product Description
Mechanism of Action
R&D Progress
nimodipine
Product Description
Mechanism of Action
R&D Progress
Edge Therapeutics, Inc. – Recent Pipeline Updates
Edge Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Edge Therapeutics, Inc., Recent Developments
Edge Therapeutics, Inc.- Press Release
Jun 08, 2012: Government Of Canada Awards CAD700,000 Toward Phase II Study Of Edge Therapeutics's Lead Compound To Improve Outcomes After Brain Injury
Apr 03, 2012: MPI Research And Edge Partner To Advance Development Of EG-1964 To Treat Brain Hemorrhage
Apr 03, 2012: MPI Research And Edge Partner To Advance Development Of NimoGel To Treat Brain Hemorrhage
Apr 03, 2012: MPI Research And Edge Partner To Advance Development Of NimoVent To Treat Brain Hemorrhage
Financial Deals Landscape
Edge Therapeutics, Inc., Deals Summary
Edge Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Edge Therapeutics Secures An Additional $0.14 Million In Series A Financing
Edge Therapeutics Secures $0.5 Million In Series A Financing
Partnerships
Edge Therapeutics Enters Into Co-Development Agreement With SurModics
Licensing Agreements
SurModics Enters Into Licensing Agreement With Edge Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Edge Therapeutics, Inc., Key Information
Edge Therapeutics, Inc., Key Facts
Edge Therapeutics, Inc. – Pipeline by Indication, 2012
Edge Therapeutics, Inc. – Pipeline by Stage of Development, 2012
Edge Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012
Edge Therapeutics, Inc. – Phase II, 2012
Edge Therapeutics, Inc. – Pre-Clinical, 2012
Edge Therapeutics, Inc. – Discovery, 2012
Edge Therapeutics, Inc. – Recent Pipeline Updates, 2012
Edge Therapeutics, Inc., Deals Summary
Edge Therapeutics Secures An Additional $0.14 Million In Series A Financing
Edge Therapeutics Secures $0.5 Million In Series A Financing
Edge Therapeutics Enters Into Co-Development Agreement With SurModics
SurModics Enters Into Licensing Agreement With Edge Therapeutics
List of Figures
Edge Therapeutics, Inc. – Pipeline by Indication, 2012
Edge Therapeutics, Inc. – Pipeline by Stage of Development, 2012
Edge Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012
Edge Therapeutics, Inc. Overview
Key Information
Key Facts
Edge Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Edge Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Edge Therapeutics, Inc. – Pipeline Products Glance
Edge Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Edge Therapeutics, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Edge Therapeutics, Inc. – Drug Profiles
aminocaproic acid
Product Description
Mechanism of Action
R&D Progress
EG-1960
Product Description
Mechanism of Action
R&D Progress
EG-1967
Product Description
Mechanism of Action
R&D Progress
nimodipine
Product Description
Mechanism of Action
R&D Progress
Edge Therapeutics, Inc. – Recent Pipeline Updates
Edge Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Edge Therapeutics, Inc., Recent Developments
Edge Therapeutics, Inc.- Press Release
Jun 08, 2012: Government Of Canada Awards CAD700,000 Toward Phase II Study Of Edge Therapeutics's Lead Compound To Improve Outcomes After Brain Injury
Apr 03, 2012: MPI Research And Edge Partner To Advance Development Of EG-1964 To Treat Brain Hemorrhage
Apr 03, 2012: MPI Research And Edge Partner To Advance Development Of NimoGel To Treat Brain Hemorrhage
Apr 03, 2012: MPI Research And Edge Partner To Advance Development Of NimoVent To Treat Brain Hemorrhage
Financial Deals Landscape
Edge Therapeutics, Inc., Deals Summary
Edge Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Edge Therapeutics Secures An Additional $0.14 Million In Series A Financing
Edge Therapeutics Secures $0.5 Million In Series A Financing
Partnerships
Edge Therapeutics Enters Into Co-Development Agreement With SurModics
Licensing Agreements
SurModics Enters Into Licensing Agreement With Edge Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Edge Therapeutics, Inc., Key Information
Edge Therapeutics, Inc., Key Facts
Edge Therapeutics, Inc. – Pipeline by Indication, 2012
Edge Therapeutics, Inc. – Pipeline by Stage of Development, 2012
Edge Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012
Edge Therapeutics, Inc. – Phase II, 2012
Edge Therapeutics, Inc. – Pre-Clinical, 2012
Edge Therapeutics, Inc. – Discovery, 2012
Edge Therapeutics, Inc. – Recent Pipeline Updates, 2012
Edge Therapeutics, Inc., Deals Summary
Edge Therapeutics Secures An Additional $0.14 Million In Series A Financing
Edge Therapeutics Secures $0.5 Million In Series A Financing
Edge Therapeutics Enters Into Co-Development Agreement With SurModics
SurModics Enters Into Licensing Agreement With Edge Therapeutics
List of Figures
Edge Therapeutics, Inc. – Pipeline by Indication, 2012
Edge Therapeutics, Inc. – Pipeline by Stage of Development, 2012
Edge Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012
